{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:38:06Z","timestamp":1769751486527,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:00:00Z","timestamp":1463443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10067-016-3300-3","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:12:03Z","timestamp":1463443923000},"page":"1985-1991","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis"],"prefix":"10.1007","volume":"35","author":[{"given":"Michele","family":"Iudici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Vettori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Giacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Capocotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,17]]},"reference":[{"key":"3300_CR1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"60","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 60:1989\u20132003","journal-title":"N Engl J Med"},{"key":"3300_CR2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bmj.313.7053.344","volume":"10","author":"LJ Walsh","year":"1996","unstructured":"Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 10:344\u20136","journal-title":"BMJ"},{"issue":"5 Suppl 68","key":"3300_CR3","first-page":"S81","volume":"29","author":"JW Jacobs","year":"2011","unstructured":"Jacobs JW, Bijlsma JW (2011) Glucocorticoids in rheumatology: indications and routes of administration. Clin Exp Rheumatol 29(5 Suppl 68):S81\u20134","journal-title":"Clin Exp Rheumatol"},{"key":"3300_CR4","first-page":"308","volume":"98","author":"J Posnik","year":"1963","unstructured":"Posnik J (1963) Systemic lupus erythematosus. The effect of corticotropin and adrenocorticoid therapy on survival rate. Calif Med 98:308\u201312","journal-title":"Calif Med"},{"key":"3300_CR5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/art.1780220901","volume":"22","author":"DA Albert","year":"1979","unstructured":"Albert DA, Hadler NM, Ropes MW (1979) Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum 22:945\u201353","journal-title":"Arthritis Rheum"},{"key":"3300_CR6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10067-013-2422-0","volume":"33","author":"M Iudici","year":"2014","unstructured":"Iudici M, Fasano S, Iacono D et al (2014) Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clin Rheumatol 33:153\u201364","journal-title":"Clin Rheumatol"},{"key":"3300_CR7","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2634","volume":"11","author":"N Hunzelmann","year":"2009","unstructured":"Hunzelmann N, Moinzadeh P, Genth E et al (2009) High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 11:R30","journal-title":"Arthritis Res Ther"},{"issue":"2 Suppl 76","key":"3300_CR8","first-page":"157","volume":"31","author":"M Iudici","year":"2013","unstructured":"Iudici M, van der Goes MC, Valentini G, Bijlsma JW (2013) Glucocorticoids in systemic sclerosis: weighing the benefits and risks\u2014a systematic review. Clin Exp Rheumatol 31(2 Suppl 76):157\u201365","journal-title":"Clin Exp Rheumatol"},{"key":"3300_CR9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.rdc.2015.08.011","volume":"42","author":"A Postolova","year":"2016","unstructured":"Postolova A, Chen JK, Chung L (2016) Corticosteroids in myositis and scleroderma. Rheum Dis Clin North Am 42:103\u201318","journal-title":"Rheum Dis Clin North Am"},{"key":"3300_CR10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0889-857X(03)00016-4","volume":"29","author":"VD Steen","year":"2003","unstructured":"Steen VD (2003) Scleroderma renal crisis. Rheum Dis Clin North Am 29:315\u201333","journal-title":"Rheum Dis Clin North Am"},{"key":"3300_CR11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/03009742.2014.957239","volume":"44","author":"M Iudici","year":"2015","unstructured":"Iudici M, Russo B, Mitidieri M, Cuomo G, Valentini G (2015) Glucocorticoids in systemic sclerosis: patients\u2019 beliefs and treatment adherence. Scand J Rheumatol 44:229\u201337","journal-title":"Scand J Rheumatol"},{"key":"3300_CR12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2133.2010.09877.x","volume":"163","author":"C Arena","year":"2010","unstructured":"Arena C, Morin AS, Blanchon T et al (2010) Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy. Br J Dermatol 163:832\u20137","journal-title":"Br J Dermatol"},{"key":"3300_CR13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","volume":"157","author":"L Fardet","year":"2007","unstructured":"Fardet L, Flahault A, Kettaneh A et al (2007) Corticosteroid-induced clinical adverse events: frequency, risk factors and patient\u2019s opinion. Br J Dermatol 157:142\u20138","journal-title":"Br J Dermatol"},{"key":"3300_CR14","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","volume":"69","author":"MC Goes van der","year":"2010","unstructured":"van der Goes MC, Jacobs JWJ, Boers M et al (2010) Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 69:1913\u201319","journal-title":"Ann Rheum Dis"},{"key":"3300_CR15","first-page":"S71","volume":"31","author":"M Mosca","year":"2013","unstructured":"Mosca M, Tani C, Aringer M (2013) Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal? Clin Exp Rheumatol 31:S71\u20134","journal-title":"Clin Exp Rheumatol"},{"key":"3300_CR16","first-page":"S93","volume":"31","author":"RA Luqmani","year":"2013","unstructured":"Luqmani RA (2013) Discontinuation of therapies in vasculitis. Clin Exp Rheumatol 31:S93\u20137","journal-title":"Clin Exp Rheumatol"},{"key":"3300_CR17","first-page":"1467","volume":"32","author":"MB Urowitz","year":"2005","unstructured":"Urowitz MB, Feletar M, Bruce IN, Iba\u00f1ez D, Gladman DD (2005) Prolonged remission in systemic lupus erythematosus. J Rheumatol 32:1467\u201372","journal-title":"J Rheumatol"},{"key":"3300_CR18","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F Hoogen van den","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis 72:1747\u201355","journal-title":"Ann Rheum Dis"},{"key":"3300_CR19","first-page":"S42","volume":"21","author":"TA Medsger Jr","year":"2003","unstructured":"Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21:S42\u20136","journal-title":"Clin Exp Rheumatol"},{"key":"3300_CR20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/rheumatology\/keq176","volume":"50","author":"G Valentini","year":"2011","unstructured":"Valentini G, Cuomo G, Abignano G et al (2011) Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 50:317\u20132","journal-title":"Rheumatology (Oxford)"},{"key":"3300_CR21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/ard.60.6.592","volume":"60","author":"G Valentini","year":"2001","unstructured":"Valentini G, Della Rossa A, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592\u20138","journal-title":"Ann Rheum Dis"},{"key":"3300_CR22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirjak L et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis 66:754\u201363","journal-title":"Ann Rheum Dis"},{"key":"3300_CR23","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202\u20135","journal-title":"J Rheumatol"},{"key":"3300_CR24","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4236","volume":"15","author":"G Valentini","year":"2013","unstructured":"Valentini G, Marcoccia A, Cuomo G et al (2013) Early systemic sclerosis: marker antibodies and video capillaroscopic findings are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther 15:R63","journal-title":"Arthritis Res Ther"},{"key":"3300_CR25","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0895-4356(98)00094-8","volume":"51","author":"G Apolone","year":"1998","unstructured":"Apolone G, Mosconi P (1998) The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 51:1025\u201336","journal-title":"J Clin Epidemiol"},{"key":"3300_CR26","first-page":"112","volume":"58","author":"G Montagna La","year":"2006","unstructured":"La Montagna G, Cuomo G, Chiarolanza I, Ruocco L, Valentini G (2006) [HAQ-DI Italian version in systemic sclerosis]. Reumatismo 58:112\u20135","journal-title":"Reumatismo"},{"key":"3300_CR27","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/jc.2015-1218","volume":"100","author":"LH Broersen","year":"2015","unstructured":"Broersen LH, Pereira AM, J\u00f8rgensen JO, Dekkers OM (2015) Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 100:2171\u201380","journal-title":"J Clin Endocrinol Metab"},{"key":"3300_CR28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2223\/JPED.1773","volume":"84","author":"C Alves","year":"2008","unstructured":"Alves C, Robazzi T, Mendonca M (2008) Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr (Rio J) 84:192\u2013202","journal-title":"J Pediatr (Rio J)"},{"key":"3300_CR29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1210\/jcem-20-3-339","volume":"20","author":"TT Amatruda","year":"1960","unstructured":"Amatruda TT, Hollingsworth D, D\u2019Esopo ND et al (1960) A study of the mechanism of the steroid withdrawal syndrome. Evidence for integrity of the hypothalamic-pituitary-adrenal system. J Clin Endocrinol Metab 20:339\u201354","journal-title":"J Clin Endocrinol Metab"},{"key":"3300_CR30","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1191\/096120399680411407","volume":"8","author":"M Corzillius","year":"1999","unstructured":"Corzillius M, Bae S (1999) Methodological issues of corticosteroid use in SLE trials. Lupus 8:692\u20137","journal-title":"Lupus"},{"key":"3300_CR31","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1002\/art.20599","volume":"11","author":"Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus","year":"2004","unstructured":"Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus (2004) Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus. Arthritis Rheum 11:3427\u20133431","journal-title":"Arthritis Rheum"},{"key":"3300_CR32","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/0961203313490434","volume":"22","author":"A AbouZaha","year":"2013","unstructured":"AbouZaha A, Fang H, Madger LS, Petri M (2013) Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. Lupus 22:697\u2013701","journal-title":"Lupus"},{"key":"3300_CR33","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/art.22198","volume":"54","author":"CE Tseng","year":"2006","unstructured":"Tseng CE, Buyon J, Kim M et al (2006) The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus. Arthritis Rheumatol 54:3623\u201332","journal-title":"Arthritis Rheumatol"},{"key":"3300_CR34","unstructured":"Luqmani R (2013) Discontinuation of therapies in vasculitis. Clin Exp Rheumatol 31(Suppl. 78):S93-S97"},{"key":"3300_CR35","first-page":"495","volume":"19","author":"RF Spiera","year":"2001","unstructured":"Spiera RF, Mitnick HJ, Kupersmith M et al (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19:495\u2013501","journal-title":"Clin Exp Rheumatol"},{"key":"3300_CR36","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/rheumatology\/ker163","volume":"50","author":"S Visvanathan","year":"2011","unstructured":"Visvanathan S, Rahman MU, Hoffman GS et al (2011) Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis\u2014a prospective longitudinal study. Rheumatology (Oxford) 50:2061\u201370","journal-title":"Rheumatology (Oxford)"},{"key":"3300_CR37","doi-asserted-by":"crossref","unstructured":"Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Ba\u0148ares A, Fernandez-Gutierrez B (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106\u201314","DOI":"10.7326\/0003-4819-134-2-200101160-00010"},{"issue":"4 Suppl 78","key":"3300_CR38","first-page":"S9","volume":"31","author":"R Caporali","year":"2013","unstructured":"Caporali R, Scir\u00e8 CA, Todoerti M, Montecucco C (2013) The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. Clin Exp Rheumatol 31(4 Suppl 78):S9\u201313","journal-title":"Clin Exp Rheumatol"},{"key":"3300_CR39","doi-asserted-by":"crossref","unstructured":"Bijlsma JW (2012) Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology (Oxford);51 Suppl 4:iv9-13","DOI":"10.1093\/rheumatology\/kes086"},{"key":"3300_CR40","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/ard.2008.095539","volume":"68","author":"T Pincus","year":"2009","unstructured":"Pincus T, Swearingen CJ, Luta G, Sokka T (2009) Efficacy of prednisone 1\u20134\u00a0mg\/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 68:1715\u201320","journal-title":"Ann Rheum Dis"},{"key":"3300_CR41","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/rheumatology\/kep250","volume":"48","author":"G Cuomo","year":"2009","unstructured":"Cuomo G, Zappia M, Abignano G, Iudici M, Rotondo A, Valentini G (2009) Ultrasonographic features of the hand and wrist in systemic sclerosis. Rheumatology 48:1414\u20137","journal-title":"Rheumatology"},{"key":"3300_CR42","doi-asserted-by":"crossref","unstructured":"Elhai M, Guerini H, Bazeli R, et al. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care & Research;8:1244\u20131249","DOI":"10.1002\/acr.21668"},{"key":"3300_CR43","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/rheumatology\/kes041","volume":"51","author":"J Avouac","year":"2012","unstructured":"Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y (2012) Articular involvement in systemic sclerosis. Rheumatology (Oxford) 51:1347\u201356","journal-title":"Rheumatology (Oxford)"},{"key":"3300_CR44","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","volume":"40","author":"VD Steen","year":"1997","unstructured":"Steen VD, Medsger TA Jr (1997) The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 40:1984\u201391","journal-title":"Arthritis Rheum"},{"key":"3300_CR45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/1529-0131(200103)44:3<653::AID-ANR114>3.0.CO;2-Q","volume":"44","author":"PJ Clements","year":"2001","unstructured":"Clements PJ, Kee Wong W, Hurwitz EL et al (2001) The Disability Index of the Health Assessment questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 44:653\u201361","journal-title":"Arthritis Rheum"},{"issue":"54","key":"3300_CR46","first-page":"32","volume":"27","author":"E Lawrence","year":"2009","unstructured":"Lawrence E, Pope J, Al Zahraly Z, Lalani S, Baron M (2009) The relationship between changes in self-reported disability (measured by the Health Assessment Questionnaire-HAQ) in scleroderma and improvement of disease status in clinical practice. Clin Exp Rheumato 27(54):32\u20137","journal-title":"Clin Exp Rheumato"},{"key":"3300_CR47","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ejim.2013.05.014","volume":"24","author":"S Dinsen","year":"2013","unstructured":"Dinsen S, Baslund B, Klose M et al (2013) Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med 24:714\u201320","journal-title":"Eur J Intern Med"},{"key":"3300_CR48","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620\u20138","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3300-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3300-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3300-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T11:44:56Z","timestamp":1718538296000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3300-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,17]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3300"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3300-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,17]]}}}